Does Induction PEG-Intron in Combination With Rebetol Enhance the Sustained Response Rates in Patients With CHC

Inclusion Criteria: * willing to give written informed consent and be able to adhere to dose and visit schedules. * 18years of age or older of either gender and any race. Subjects who are over 65 years of age must be in generally good health. * Serum positive for HCV-RNA by PCR assay Treatment naïve Genotype 1 \& 4 HCV participants * ALT either elevated or persistently normal * Liver biopsy within 36 months with a pathology report confirming the histological diagnosis is consistent with CHC * Compensated liver disease with the following minimum hematologic, biochemical, and serologic criteria at the Entry Visit * Hemoglobin values of \<12 gm/dL for females \& \<13 gm/dL for males. * WBC \<3,000/mm3 * Neutrophil count \< 1,500/mm3 * Platelets \<65,000/mm3 * Direct bilirubin, within 20% of (ULN) * Indirect bilirubin, WNL (unless non-hepatitis related factors such as Gilbert's disease explain an indirect bilirubin rise * Albumin, WNL * Serum creatinine, within 20% of ULN * Glucose should be less than 115 mg/dL * Thyroid Stimulating Hormone (TSH), WNL * HIV negative * HBsAg negative * Alpha fetoprotein value \< 100 ng/mL obtained within one year prior to entry for patients with Stage 3 or 4 liver disease * Reconfirmation \& documentation sexually active female subjects of childbearing potential are practicing adequate contraception during the treatment period \& 6 months following the last dose of study medication * Reconfirmation that sexually active male subjects are practicing acceptable methods of contraception during the treatment period \& for 6 months following the last dose of study medication Exclusion Criteria: * Women who are pregnant or nursing. * Hepatitis C of non-genotype 1 or 4 * Previous anti-viral therapy * Suspected hypersensitivity to interferon, PEG-interferon, ribavirin * Any other cause for the liver disease other than chronic hepatitis C including but not limited to: * Co-infection with HBV * Hemochromatosis * Alpha-1 antitrypsin deficiency * Wilson's disease * Autoimmune hepatitis * Alcoholic liver disease * Obesity-induced liver disease * Drug-related liver disease * Hemophilia or any other condition that would prevent the subject from having a liver biopsy, including anticoagulant therapy * Hemoglobinopathies * Evidence of advanced liver disease (ascites, bleeding varices,spontaneous encephalopathy) * organ transplants other than cornea and hair transplant. * Any known preexisting medical condition that could interfere with the subject's participation in and completion of the protocol such as:Preexisting psychiatric condition, especially severe depression, or a history of severe psychiatric disorder, such as major psychoses, suicidal ideation and/or suicidal attempt are excluded * CNS trauma or active seizure disorders requiring medication * Significant cardiovascular dysfunction within the past 12 months. Subjects with ECG showing clinically significant abnormalities * Poorly controlled DM * Chronic pulmonary disease (COPD)with documented pulmonary hypertension * Immunologically mediated disease (e.g., inflammatory bowel disease, RA, idiopathic thrombocytopenia purpura, lupus, autoimmune hemolytic anemia, scleroderma, severe psoriasis, clinical cryoglobulinemia with vasculitis) * Any medical condition requiring, or likely to require during the course of the study, chronic systemic administration of steroids * Active gout * Substance abuse * not willing to be abstain from the consumption of alcohol. * clinically significant retinal abnormalities * Any other condition that in the opinion of the Investigator would make the subject unsuitable for enrollment, or could interfere with the subject participating in and completing the protocol * Known HIV Positive